By going hybrid-virtual, we can draw from the insight of leading-edge scientific collaborators, learn from the deep domain expertise of contract development and manufacturing organizations (CDMOs), and leverage the experience of seasoned advisors to guide our science and strategy. We keep our focus where it matters – our research.
There is both elegance and efficiency in simplicity, and that’s why it drives our scientific approach and our strategy. Given equal results, a simpler solution will always be better – not just for patients, but as a foundation for future breakthroughs.
We’re passionate about our technology and the innovative science that underpins it. But we measure our success in the positive impact that our work has on the health and wellbeing of patients and their families.
We see ourselves as disruptors in the gene therapy space. But we don’t have all the answers – in fact, no one does. We see collaboration as the path to innovation, bringing together smart people and novel ideas to create new possibilities.
We’re creating a culture where people come first, and where personal accountability fosters a healthy organization. At the same time, we strive to find joy in our work, never taking ourselves too seriously. We believe that play is at the heart of innovation, and that humor and joy open us to new ways of thinking.